A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis Clinical Trial

Official title:

A Phase 1, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AK120 in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04256174
• Other study ID #: AK120-101
• Status: Completed
• Phase: Phase 1
• Start date: June 15, 2020
• Est. completion date: October 29, 2021

Study information

• Verified date: August 2022
• Source: Akeso
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A dose escalation, first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of AK120 in healthy subjects and subjects with moderate- to- severe atopic dermatitis

Description:

This is a phase 1, randomized, two-part, double-blind, placebo-controlled, dose-escalation, first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of AK120 in healthy subjects (part 1, single ascending dose) and subjects with moderate- to- severe atopic dermatitis(part 2, multiple ascending dose)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: October 29, 2021
• Est. primary completion date: October 29, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Major Inclusion Criteria:

Subjects must meet all the following inclusion criteria (as applicable) to be eligible for participation in this study:

Part 1:

1. Willing and able to understand and sign an Informed Consent Form (ICF).

2. Women or men between 18 and 55 years of age, inclusive, at screening.

3. Must have a calculated body mass index within 18.0 to 30.0 kg/m2 (inclusive) at screening, and a total body weight =50 kg for men or =45 kg for women at screening and Day -1 before randomization.

4. Women of childbearing potential who are sexually active must use one of the permitted methods of contraception from screening until at least 180 days after dosing of study medication.

5. Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use an effective method of contraception from Day 1 through 180 days after dosing of study medication.

6. Must, in the opinion of the Investigator, be in good general health based upon medical history, physical examination (including vital signs), and 12-lead ECG; and clinical laboratory tests

Part 2:

1. Male or female, aged 18 to 65 years (inclusive) at time of Screening.

2. Chronic atopic dermatitis (AD) diagnosed by the revised Hanifin and Rajka criteria that has been present for at least 1 year before the Screening visit.

3. EASI score =12 at the screening and baseline visits.

4. IGA score =3 at the screening and baseline visits.

5. BSA of AD involvement =10% at the screening and baseline visits.

6. History of an inadequate response or medically inappropriate use of topical drug treatment, in the judgment of the Investigator, to AD treatment with a topical regimen of corticosteroids, phosphodiesterase inhibitors or calcineurin inhibitors or with phototherapy within 6 months of the Screening visit.

7. Subjects must be applying stable doses of an additive-free, basic bland emollient twice daily for at least 7 days before the baseline visit.

Major Exclusion Criteria:

Subjects who meet any of the following exclusion criteria will not be enrolled in this study:

Part 1:

1. Clinically significant clinical safety laboratory result, or blood pressure or electrocardiogram (ECG) abnormalities.

2. Current acute infection or history of acute infection within 7 days prior to receipt of the study drug.

3. Have a recent history of conjunctivitis or keratitis within 6 months prior to screening.

4. History or complications of tuberculosis, or evidence of latent tuberculosis by QuantiFERON®-TB Gold screening.

5. Are positive for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus (HIV) at screening.

Part 2:

1. The washout period for prior drug therapy (eg. corticosteroids, immunosuppressive/immunomodulating, biologics, phototherapy, Chinese medicine,anti-infective agents) is inadequate.

2. Any medical or psychiatric condition, laboratory or ECG parameter which, in the opinion of the Investigator or the Sponsor's medical monitor, would place the subject at risk, interfere with participation in the study, or interfere with the interpretation of study results.

3. History of exposure to active TB, and/or history or current evidence of TB infection; and/or Chest X-ray showed old TB lesions at Screening or within 3 months before the Screening visit ..

4. Positive results at Screening for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C antibody with positive hepatitis C virus (HCV) RNA polymerase chain reaction; positive HIV serology at screening.

5. Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC) within 6 months before the baseline visit.

6. History of clinical parasite infection, recent or planned travel to an area with endemic parasite infection within 6 months before the Screening visit

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• AK120 or placebo- Part 1- Cohort 1
Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects
• AK120 or placebo- Part 1- Cohort 2
Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects
• AK120 or placebo- Part 1- Cohort 3
Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects
• AK120 or placebo- Part 1- Cohort 4
Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects
• AK120 or placebo- Part 1- Cohort 5
Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects
• AK120 or placebo- Part 2- Cohort 1
Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
• AK120 or placebo- Part 2- Cohort 2
Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
• AK120 or placebo- Part 2- Cohort 3
Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
• AK120 or placebo- Part 2- Cohort 4
Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.

Locations

Country	Name	City	State
Australia	CMAX Clinical Research	Adelaide
Australia	Emeritus Sydney	Botany	New South Wales
Australia	Emeritus Melbourne	Camberwell	Victoria
Australia	Sinclair Dermatology	East Melbourne
Australia	Peninsula Specialist Centre	Kippa-Ring
Australia	Scientia Clinical Research Ltd	Randwick
New Zealand	Optimal Clinical Trials	Auckland
New Zealand	Southern Clinical Trials - Waitemata	Birkenhead	Auckland
New Zealand	Christchurch Clinical Studies Trust	Christchurch
New Zealand	Southern Clinical Trials - Christchurch	Christchurch
New Zealand	P3 Research Hawkes Bay	Havelock North
New Zealand	P3 Research Tauranga	Tauranga
New Zealand	P3 Research Wellington	Wellington

Sponsors (1)

Lead Sponsor	Collaborator
Akesobio Australia Pty Ltd

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events(AEs)/serious adverse events(SAEs)	Incidence of treatment emergent adverse events(AEs)/serious adverse events(SAEs)	From signing of informed consent through through 12 weeks post-dose
Secondary	Thymus and activation regulated chemokine (TARC)/Chemokine Ligand 17(CCL17)	Change from baseline in serum levels of thymus activation and regulated chemokine (TARC)/Chemokine Ligand 17 (CCL17) in serum	From baseline through 12 weeks post-dose
Secondary	Maximum observed serum concentration (Cmax)	Maximum observed serum concentration (Cmax) of AK120	From baseline through 12 weeks post-dose
Secondary	Area under the concentration-time curve (AUC)	Area under the concentration-time curve (AUC) of serum concentration of AK120	From baseline through 12 weeks postdose
Secondary	Anti-drug antibodies(ADAs)	Number and percentage of subjects who develop detectable anti-drug antibodies(ADAs)	From baseline through 12 weeks postdose
Secondary	Investigator global assessment (IGA) (part 2)	The proportion of subjects with Investigator global assessment (IGA) 0 to 1 and subjects with IGA reduction from baseline of = 2-point.; IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a static 6-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe;5 = very severe) based on erythema and papulation/infiltration.	From baseline through 12 weeks postdose
Secondary	Pruritus-Numeric Rating Scale (P-NRS) (part 2)	The proportion of subjects with Pruritus-Numeric Rating Scale (P-NRS) improvement (reduction) from baseline of = 3-point.; Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable])	From baseline through 12 weeks postdose
Secondary	Change from baseline in Eczema Area and Severity Index (EASI) score(part 2)	The EASI score was used to measure the severity and extent of atopic dermatitis (AD). The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.	From baseline through 12 weeks postdose
Secondary	Change from baseline in body surface area (BSA) of AD involvement. (part 2)	Body surface area determined by palm method where 1 palm is equivalent to 1%. Total body surface area ranges from 1% to 100%, with the higher body surface area reflecting the worse severity of AD.	From baseline through 12 weeks postdose